AtriCure Stock News

AtriCure (ATRC) delivered earnings and revenue surprises of -6.67% and 6.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan

Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged. The analysts write that ATRC broke out cryoSPHERE into a n

Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan

AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AtriCure Inc. (NASDAQ:ATRC ) Q1 2022 Results Conference Call May 3, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Michael Carrel - President, CEO Angela Wirick - CFO Conference C

AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) delivered earnings and revenue surprises of 2.07% and 1.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Related Stocks: ATRC , KROS , BCYC , CDXS , PFE , MEIP , BLU , FNA , NGM , MRTX , CRNX , PLRX , ALDX , XBI , YMAB , STIM , APTO , WW ,

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the posit

AtriCure Inc (NASDAQ: ATRC ) reported Q4 FY21 sales of $73.2 million , an increase of 26.8% Y/Y (+27.4% on a constant currency basis), beating the consensus of $72.65 million. U.S. revenue was $61.2 million, increasing 29.1% reflected strong growth across all product lines, driven by sales of cryoSPHERE, EPi-Sense, and AtriClip Flex⋅V products. International revenue increased 16.3% (+19.3% on a constant currency basis) to … Full story available on Benzinga.com

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the posit

AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?